Positron

Positron Corporation is a molecular imaging medical device company that specializes in the development and commercialization of positron emission tomography (PET) and PET-computed tomography (PET-CT) imaging systems for cardiac and oncology applications. The company's flagship product is the Attrius PET scanner, a dedicated PET system designed specifically for cardiac imaging studies. Positron's Attrius PET leverages specialized cardiac software and state-of-the-art imaging technology, establishing the company as a leader in nuclear cardiology.

Positron is currently focused on the development and commercialization of its new Affinity PET-CT 4D device, a state-of-the-art molecular imaging system that combines PET and CT capabilities. The Affinity PET-CT 4D is designed to meet the needs of both cardiologists and oncologists, enabling them to utilize the full capabilities of molecular imaging and nuclear medicine. In March 2023, Positron executed a clinical study agreement with Ochsner Clinic Foundation for the evaluation of the Affinity PET-CT 4D device, in preparation for obtaining FDA approval. The company expects to complete the clinical study and receive FDA certification within the next 60 days as of March 2023.

Positron's business model revolves around providing comprehensive solutions to healthcare providers, including state-of-the-art imaging systems, clinical services, and practice solutions. The company's products and services aim to enable accurate diagnosis of coronary artery disease, improve patient outcomes, and facilitate cost-effective medical practices. In June 2024, Positron joined the Cardiac PET Industry Coalition (CPIC), a national alliance dedicated to advancing cardiovascular PET imaging and promoting fair coverage and reimbursement policies for cardiac PET diagnostics.

Key customers and partnerships

In June 2023, Positron entered into an agreement with Neusoft Medical Systems, a leading medical device manufacturer, to purchase the inventory of Attrius PET systems and components. The acquisition of six Attrius PET systems and related components, valued at approximately USD 6 million, positions Positron to meet the growing demand for dedicated cardiac PET solutions through a "Lease to Own/Services Program." This program offers healthcare providers an attractive operational model by providing an Attrius PET system and comprehensive clinical and technical services for a monthly fee, with ownership transferred to the customer upon completion of the lease term.